Literature DB >> 18427766

[Histopathology of urothelial carcinomas: crucial for patient management].

K Lindemann-Docter1, R Knüchel-Clarke.   

Abstract

Urothelial carcinomas include tumors with very different clinical outcomes: 70-80% of urothelial carcinomas are genetically stable and are associated with a favorable prognosis, but 20-30% are genetically unstable and have a high progression rate. Therefore, the current World Health Organization classification (2004) differentiates the histologic grade as low grade (LG) or high grade (HG). Unequivocal language is mandatory to optimize therapy and assess prognosis. In addition to TNM classification and histologic grade, genetic factors such as mutations of p53, fibroblast growth factor receptor 3 (FGFR3), and phosphatidylinositol-3-kinase (PIK(3)CA) are relevant in patients' prognoses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427766     DOI: 10.1007/s00120-008-1736-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses.

Authors:  E C Obermann; K Junker; R Stoehr; W Dietmaier; D Zaak; J Schubert; F Hofstaedter; R Knuechel; A Hartmann
Journal:  J Pathol       Date:  2003-01       Impact factor: 7.996

2.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Authors:  Elena López-Knowles; Silvia Hernández; Núria Malats; Manolis Kogevinas; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Consol Serra; Francisco X Real
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

3.  Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract.

Authors:  C Hafner; R Knuechel; L Zanardo; W Dietmaier; H Blaszyk; J Cheville; F Hofstaedter; A Hartmann
Journal:  Oncogene       Date:  2001-08-09       Impact factor: 9.867

4.  Histologic-genetic mapping by allele-specific PCR reveals intraurothelial spread of p53 mutant tumor clones.

Authors:  Robert Stoehr; Ruth Knuechel; Joerg Boecker; Hagen Blaszyk; Ruediger Schmitt; Thomas Filbeck; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Lab Invest       Date:  2002-11       Impact factor: 5.662

Review 5.  Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.

Authors:  Timothy D Jones; Liang Cheng
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

6.  Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.

Authors:  Edwin Hungerhuber; Herbert Stepp; Martin Kriegmair; Christian Stief; Alfons Hofstetter; Arndt Hartmann; Ruth Knuechel; Alexander Karl; Stefan Tritschler; Dirk Zaak
Journal:  Urology       Date:  2007-02       Impact factor: 2.649

Review 7.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Authors:  Anirban P Mitra; Ram H Datar; Richard J Cote
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

Review 8.  Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies.

Authors:  Christian Hafner; Ruth Knuechel; Robert Stoehr; Arndt Hartmann
Journal:  Int J Cancer       Date:  2002-09-01       Impact factor: 7.396

  8 in total
  4 in total

1.  [Use of marker systems in the treatment of bladder cancer].

Authors:  M Burger; F Vom Dorp
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

2.  [Update on urothelial carcinoma histopathology].

Authors:  K Lindemann-Docter; R Knüchel
Journal:  Pathologe       Date:  2008-09       Impact factor: 1.011

Review 3.  [Preneoplastic lesions and precursors of urothelial cancer].

Authors:  R Knüchel-Clarke; N T Gaisa
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

Review 4.  [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification--food for thought].

Authors:  R Knüchel; K Lindemann-Docter
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.